Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-24
2011-05-24
Jarrell, Noble (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S469000
Reexamination Certificate
active
07947671
ABSTRACT:
Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided.
REFERENCES:
patent: 5089273 (1992-02-01), Rinehart et al.
patent: 5149804 (1992-09-01), Rinehart et al.
patent: 5256663 (1993-10-01), Rinehart et al.
patent: 5478932 (1995-12-01), Rinehart et al.
patent: 5552544 (1996-09-01), Brana et al.
patent: 5654426 (1997-08-01), Rinehart et al.
patent: 5721362 (1998-02-01), Corey et al.
patent: 5908835 (1999-06-01), Bissery
patent: 5985876 (1999-11-01), Rinehart et al.
patent: 6124292 (2000-09-01), Corey
patent: 6124293 (2000-09-01), Rinehart et al.
patent: 6153590 (2000-11-01), Andersen et al.
patent: 6316214 (2001-11-01), Rinehart et al.
patent: 6348467 (2002-02-01), Corey
patent: 6544560 (2003-04-01), Bullent et al.
patent: 6569859 (2003-05-01), Corey
patent: 6686470 (2004-02-01), Danishefsky et al.
patent: 6712023 (2004-03-01), Targotay et al.
patent: 6815544 (2004-11-01), Corey
patent: 6867334 (2005-03-01), Rinehart et al.
patent: 7115743 (2006-10-01), Rinehart
patent: 7202361 (2007-04-01), Flores et al.
patent: 7241892 (2007-07-01), Cuevas et al.
patent: 7247629 (2007-07-01), Manzanares et al.
patent: 7309601 (2007-12-01), Perez Esteban et al.
patent: 7410969 (2008-08-01), Manzanares et al.
patent: 7420051 (2008-09-01), Francesch
patent: 7524956 (2009-04-01), Cuevas et al.
patent: 7622458 (2009-11-01), Rybak
patent: 7767659 (2010-08-01), Barrasa et al.
patent: 2002/0137663 (2002-09-01), Forman et al.
patent: 2003/0216397 (2003-11-01), Flores et al.
patent: 2004/0002602 (2004-01-01), Francesch
patent: 2004/0019027 (2004-01-01), Forman et al.
patent: 2004/0019056 (2004-01-01), Manzanares et al.
patent: 2004/0108086 (2004-06-01), Takahashi et al.
patent: 2006/0030571 (2006-02-01), Rinehart et al.
patent: 2006/0094687 (2006-05-01), Beijnen et al.
patent: 2006/0106021 (2006-05-01), Martinez et al.
patent: 2007/0004691 (2007-01-01), Donald et al.
patent: 2007/0082856 (2007-04-01), Gianni et al.
patent: 2007/0128201 (2007-06-01), D'Incalci et al.
patent: 2008/0234279 (2008-09-01), Rinehart et al.
patent: 0 309 477 (1991-11-01), None
patent: 59-225189 (1984-12-01), None
patent: 60-84288 (1985-05-01), None
patent: WO 87/07610 (1987-12-01), None
patent: WO 92/09607 (1992-06-01), None
patent: WO 98/12198 (1998-03-01), None
patent: WO 98/46080 (1998-10-01), None
patent: WO 99/52138 (1999-10-01), None
patent: WO99/58125 (1999-11-01), None
patent: WO 00/18233 (2000-04-01), None
patent: WO 00/69441 (2000-11-01), None
patent: WO 00/69862 (2000-11-01), None
patent: WO 01/77115 (2001-10-01), None
patent: WO 01/87894 (2001-11-01), None
patent: WO 01/87895 (2001-11-01), None
patent: WO 02/36135 (2002-05-01), None
patent: WO 02/064843 (2002-08-01), None
patent: WO 03/008423 (2003-01-01), None
patent: WO 03/020259 (2003-03-01), None
patent: WO 03/039571 (2003-05-01), None
patent: WO 2005/049029 (2005-06-01), None
patent: WO 2005/049030 (2005-06-01), None
patent: WO 2005/049031 (2005-06-01), None
patent: WO 2006/035244 (2006-04-01), None
patent: WO 2006/046080 (2006-05-01), None
patent: WO 2009/050303 (2009-04-01), None
patent: WO 2009/138509 (2009-11-01), None
patent: WO 2009/140675 (2009-11-01), None
Arai, T. et al., “The Structure of a Novel Antitumor Antibiotic, Saframycin A,” Experientia, vol. 36, pp. 1025-1027, 1980.
Arai, Tadashi et al., “Directed Biosynthesis of New Saframycin Derivatives with Resting Cells ofStreptomyces lavendulae”, Antimicrobial Agents and Chemotherapy, vol. 28, No. 1, pp. 5-11, 1985.
Arai, Tadashi etal., “Increased Production of Saframycin A and Isolation of Saframycin S,” The Journal of Antibiotics, vol. XXXIII, No. 9, pp. 951-960, 1980.
Arai, Tadashi et al., “Isoquinolineinones from Actinomycetes and Sponges”, The Alkaloids Chemistry and Pharmacology, vol. XXI, pp. 56-100, 1983.
Arai, Tadashi et al., “New Antibiotics, Safraycins A, B, C, D and E”, The Journal of Antibiotics, vol. XXX, No. 11, pp. 1015-1018, 1977.
Asaoka, Takemitsu et al., “A New Saframycin, Saframycin R”, The Journal of Antibiotics, vol. XXXV, No. 12, pp. 1708-1710, 1982.
Barton, Derek H.R. et al, Synthesis and Properties of a Series of Sterically Hindered Guanidine.
Bonfanti et al., Effect of Ecteinascidin-743 on the Interaction Between DNA Binding Proteins and DNA. Anticancer Drug Des. 14, 179-86, 1999.
Brown, J.M., “NCI's Anticancer Drug Screening Program May Not Be Selecting for Clinically Active Compounds,” Oncol. Res. 95:213-215, 1997.
Cable, Karl M. et al., “The Biosynthesis of Tuberin from Tyrosine and Giycine; Observations on the Stereochemistry Associated with the Conversion of Glycine through Methylenetetrahydrofolate into Methenyltetrahydrofolate,” Journal of the Chemical Society Perkins Transactions I, No. 7, pp. 1593-1598, 1987.
Calabresi et al., “Chemotherapy of Neoplastic Diseases”, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed, New York: McGraw-Hill, 1996, pp. 1225-1229.
Cancer definition, http://www.medterms.com/script/main/artasp?articlekey=2580, accessed Nov. 27, 2007.
Cecil Textbook of Medicine Bennet, J.C. and Plum, F., eds. 20th Edition, vol. 1, pp. 1004-1010 1996.
Cecil Texbook of Medicine, 20 Edition 2000, Goldman & Bennett Editors, W.B. Saunders Company Publisher, Chapter 198, pp. 1060-1074.
Cecil Textbook of Medicine Goldman & Bennett, eds. 21st Edition, Chapter 198, 2000, pp. 1060-1074.
Chabner, “Cytotoxic agents in the era of molecular targets and genomics,” The Oncologist, vol. 7, suppl. 3, pp. 34-41, 2002.
Committee on Risk Assessment Methodology, “Issues in Risk Assessment. Appendix A: Workshop Summary—Maximum Tolerated Dose: Implications for Risk Assessment,” National Research Council, National Academy of Sciences, National Academies Press, Washington DC, pp. 79-89, 1993.
Cooper, Raymond et al., “Structure of the Quinone Antibiotic EM5519 and the Behavior of Quinones in Fast Atom Bombardment Mass Spectrometry,” The Journal of Antibiotics, vol. XXXVIII, No. 1, pp. 24-30 1985.
Corey, E.J. et al., “Enantioselective Total Synthesis of Ecteinascidin 743,” Journal of the American Chemical Society, vol. 118, No. 38, pp. 9202-9203, 1996.
Cuevas, Carmen et al., “Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B”, Organic Letters, vol. 2, No. 16, pp. 2545-2548, 2000.
Cvitkovic, E. et al., “Ecteinascidin-743 ET-743 24 hour continuous intravenous infusion CI phase I study tumors ST patients,” Annals Oncology, Abstract 456, 1998.
Delaloge, S. et al., “Ecteinascidin-743: A Marine-Derived Compound in Advanced Pretreated Sarcoma Patients—Preliminary Evidence of Activity”, J. of Clinical Oncology, vol. 19, No. 5, pp. 1248-1255, 2001.
DeVita et al., “Combination Versus Single Agent Chemotherapy: A Review of the Basis for Selection of Drug Treatment of Cancer”, Cancer, vol. 35, pp. 98-110, 1975.
Draetta, G. and Pagano, M., “Annual Reports in Medicinal Chemistry vol. 31,” Academic Press, San Diego, pp. 241-246, 1996.
D'Incalci et al., “Mode of action of Ecteinascidin-743 ET-743,” Proceedings of the 1999 AACR-NCI-EORTC International Conference, Clinical Cancer Research, vol. 5, Supplement, pp. 3872s-3873s, Abstract of Plenary Session 7, Nov. 16-19, 1999.
D'Incalci et al., “Preclinical and Clinical Results with the Natural Marine Product ET-743,” Expert Opin. Investig. Drugs, 1211:1843-1853, 2003.
D'Incalci et al., “Unique Features of the Mode of Action of ET-743”, The Oncologist, 7, p. 210-216, Jun. 2002.
Dorwald, Florencio Zaragoza, Side Reactions in Organic Synthesis: A Guide to Syccessfull Synthesis Design, Wiley, VCH, Weinheim, pp. IX of Preface, 2005.
Drugs Fut., “Ecteinascidin-743” vol. 22, No. 11, p. 1279, 1997.
Eckhardt, S.G. et al., “Activity of ecteinascidin, a novel marine cytotoxic, against primary human tumor
Barrasa Valentin Martinez
Cuevas Carmen
Gallego Pilar
Manzanares Ignacio
Menchaca Roberto
Jarrell Noble
King & Spalding LLP
Pharma Mar S.A.
Sonnenfeld Kenneth H.
LandOfFree
Synthesis of naturally occuring ecteinascidins and related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of naturally occuring ecteinascidins and related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of naturally occuring ecteinascidins and related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649155